TY - JOUR
T1 - Vitreoretinal Interface Changes After Anti-vascular Endothelial Growth Factor Treatment in Highly Myopic Eyes
T2 - A Real-World Study
AU - Tsui, Mei Chi
AU - Hsieh, Yi Ting
AU - Lai, Tso Ting
AU - Hsia, Yun
AU - Wang, Shih Wen
AU - Ma, I. Hsin
AU - Hung, Kuo Chi
AU - Lin, Chang Pin
AU - Yang, Chang Hao
AU - Yang, Chung May
AU - Ho, Tzyy Chang
N1 - Funding Information:
No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/6
Y1 - 2023/6
N2 - Introduction: To investigate changes in the vitreoretinal interface after anti-vascular endothelial growth factor (anti-VEGF) treatment in highly myopic eyes. Methods: Eyes with myopic choroidal neovascularization (mCNV) treated with intravitreal injection of anti-VEGF in a single-center were retrospectively reviewed. Fundus abnormalities and features of optical computed tomography were studied. Results: A total of 295 eyes from 254 patients were recruited to the study. Prevalence of myopic macular retinoschisis (MRS) was 25.4%, and the rates of progression and onset of MRS were 75.9% and 16.2%, respectively. Outer retinal schisis (β = 8.586, p = 0.003) and lamellar macular hole (LMH) (β = 5.015, p = 0.043) at baseline were identified risk factors for progression and onset of MRS, whereas male sex (β = 9.000, p = 0.039) and outer retinal schisis at baseline (β = 5.250, p = 0.010) were risk factors for MRS progression. Progression of MRS was first detected in outer retinal layers in 48.3% of eyes. Thirteen eyes required surgical intervention. Spontaneous improvements of MRS were observed in five eyes (6.3%). Conclusion: Changes in the vitreoretinal interface, such as progression, onset, and improvement of MRS, were observed after anti-VEGF treatment. Outer retinal schisis and LMH were risk factors of progression and onset of MRS after anti-VEGF treatment. Intravitreal injection of ranibizumab and retinal hemorrhage were protective factors for surgical intervention for vision-threatening MRS.
AB - Introduction: To investigate changes in the vitreoretinal interface after anti-vascular endothelial growth factor (anti-VEGF) treatment in highly myopic eyes. Methods: Eyes with myopic choroidal neovascularization (mCNV) treated with intravitreal injection of anti-VEGF in a single-center were retrospectively reviewed. Fundus abnormalities and features of optical computed tomography were studied. Results: A total of 295 eyes from 254 patients were recruited to the study. Prevalence of myopic macular retinoschisis (MRS) was 25.4%, and the rates of progression and onset of MRS were 75.9% and 16.2%, respectively. Outer retinal schisis (β = 8.586, p = 0.003) and lamellar macular hole (LMH) (β = 5.015, p = 0.043) at baseline were identified risk factors for progression and onset of MRS, whereas male sex (β = 9.000, p = 0.039) and outer retinal schisis at baseline (β = 5.250, p = 0.010) were risk factors for MRS progression. Progression of MRS was first detected in outer retinal layers in 48.3% of eyes. Thirteen eyes required surgical intervention. Spontaneous improvements of MRS were observed in five eyes (6.3%). Conclusion: Changes in the vitreoretinal interface, such as progression, onset, and improvement of MRS, were observed after anti-VEGF treatment. Outer retinal schisis and LMH were risk factors of progression and onset of MRS after anti-VEGF treatment. Intravitreal injection of ranibizumab and retinal hemorrhage were protective factors for surgical intervention for vision-threatening MRS.
KW - Anti-vascular endothelial growth factor
KW - High myopia
KW - Myopic choroidal neovascularization
KW - Myopic macular retinoschisis
KW - Myopic traction maculopathy
KW - Vitreoretinal interface
UR - http://www.scopus.com/inward/record.url?scp=85151464059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151464059&partnerID=8YFLogxK
U2 - 10.1007/s40123-023-00701-4
DO - 10.1007/s40123-023-00701-4
M3 - Article
AN - SCOPUS:85151464059
SN - 2193-8245
VL - 12
SP - 1693
EP - 1710
JO - Ophthalmology and Therapy
JF - Ophthalmology and Therapy
IS - 3
ER -